{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:17:10Z","timestamp":1780381030579,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.07.007","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T18:06:50Z","timestamp":1595354810000},"page":"5923-5926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 \u2013 2019"],"prefix":"10.1016","volume":"38","author":[{"given":"Pedro L.","family":"Moro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Jane","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2020.07.007_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6803a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019\u201320 Influenza Season","volume":"68","author":"Grohskopf","year":"2019","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.vaccine.2020.07.007_b0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.03.008","article-title":"Immunosenescence: Influenza vaccination and the elderly","volume":"29","author":"Haq","year":"2014","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.vaccine.2020.07.007_b0015","doi-asserted-by":"crossref","unstructured":"Isakova-Sivak I, Grigorieva E, Rudenko L. Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines. Expert Rev Vaccines. 2020 Jan 4. doi: 10.1080\/14760584.2020.1711056. [Epub ahead of print","DOI":"10.1080\/14760584.2020.1711056"},{"key":"10.1016\/j.vaccine.2020.07.007_b0020","unstructured":"Fluzone High-dose package insert. https:\/\/www.fda.gov\/media\/119870\/download accessed January 8, 2020"},{"key":"10.1016\/j.vaccine.2020.07.007_b0025","doi-asserted-by":"crossref","unstructured":"Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK; QHD00013 Study Group. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults \u226565\u00a0years of age: A phase 3 randomized clinical trial. Vaccine. 2019 Sep 16;37(39):5825-5834","DOI":"10.1016\/j.vaccine.2019.08.016"},{"key":"10.1016\/j.vaccine.2020.07.007_b0030","doi-asserted-by":"crossref","unstructured":"Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Clin Infect Dis. 2012; 54(11):1608-14","DOI":"10.1093\/cid\/cis256"},{"issue":"21","key":"10.1016\/j.vaccine.2020.07.007_b0035","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.vaccine.2017.03.092","article-title":"Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine."},{"issue":"36","key":"10.1016\/j.vaccine.2020.07.007_b0040","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine."},{"issue":"28","key":"10.1016\/j.vaccine.2020.07.007_b0045","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000\u20132013","volume":"33","author":"Hibbs","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.07.007_b0050","unstructured":"Medical Dictionary for Regulatory Activities. Available at: https:\/\/www.meddra.org\/ Accessed January 9, 2020."},{"key":"10.1016\/j.vaccine.2020.07.007_b0055","first-page":"52252","article-title":"21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Vol 62","author":"Food and Drug Administration","year":"1997","journal-title":"Fed Reg"},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.007_b0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.07.007_b0065","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.007_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2020.07.007_b0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vaccine.2020.07.007_b0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/14760584.1.2.161","article-title":"Methods of ensuring vaccine safety","volume":"1","author":"Ball","year":"2002","journal-title":"Expert Rev Vaccines."},{"issue":"6","key":"10.1016\/j.vaccine.2020.07.007_b0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.vaccine.2020.07.007_b0090","unstructured":"Heron M. Deaths: Leading causes for 2017. National Vital Statistics Reports; vol 68 no 6. Hyattsville, MD: National Center for Health Statistics. 2019. Available at https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_06-508.pdf. Accessed January 13, 2020"},{"key":"10.1016\/j.vaccine.2020.07.007_b0095","unstructured":"In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 19e New York, NY: McGraw-Hill; 2014. Allergies, Anaphylaxis, and Systemic Mastocytosis http:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=1130&sectionid=79720773 Accessed February 12, 2020."},{"issue":"3","key":"10.1016\/j.vaccine.2020.07.007_b0100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.vaccine.2020.07.007_b0105","unstructured":"In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 19e New York, NY: McGraw-Hill; 2014. Guillain-Barr\u00e9 Syndrome and Other Immune-Mediated Neuropathies http:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=1130&sectionid=79720773 Accessed February 12, 2020."},{"issue":"2","key":"10.1016\/j.vaccine.2020.07.007_b0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.vaccine.2020.07.007_b0115","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.1980.03300500016019","article-title":"Guillain Barr\u00e9 Syndrome in recipients of A\/New Jersey influenza vaccine","volume":"243","author":"Marks","year":"1980","journal-title":"JAMA"},{"issue":"42","key":"10.1016\/j.vaccine.2020.07.007_b0120","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.07.007_b0125","unstructured":"Fluzone High dose quadrivalent package insert: https:\/\/www.fda.gov\/media\/119870\/download Accessed April 25, 2020"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:50Z","timestamp":1759401950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":25,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X20309075"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 \u2013 2019","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}